Endogenous opioid systems and alcohol addiction.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical pharmacology, animal models, and clinical mechanisms.
PubMed 9040115 · doi:10.1007/s002130050169
What was done
This narrative review synthesizes neurochemical, animal behavioral (rodents and primates), and clinical literature regarding how endogenous opioid systems (mu, delta, and kappa receptors and their ligands) interact with mesolimbic dopamine pathways to mediate alcohol reinforcement and addiction.
What was found
The abstract reports no numeric values. Directionally, it notes that low doses of morphine increase while high doses decrease alcohol self-administration in animals. Non-selective opioid antagonists (naloxone, naltrexone) and selective mu- or delta-receptor antagonists decrease alcohol consumption across experimental conditions, aligning with clinical evidence where opioid antagonists help prevent relapse in individuals with alcohol addiction.
Why it matters
This work integrates neurobiological and behavioral evidence to explain how alcohol engages endogenous opioid reward circuitry, providing mechanistic rationale for targeting opioid receptors in treating alcohol use disorder.
Limits
The abstract provides no sample sizes, effect sizes, or quantitative data. As a narrative review, it lacks a systematic search strategy and quality appraisal, relying substantially on preclinical animal models rather than direct human clinical trial data.
Cited by
- supports Alcohol acts upon the endogenous opioid system in the brain.